EVerZom Raises €10M to Advance Exosome-Based Regenerative Therapies

Deal Summary

Strasbourg-based biotech EVerZom raised €10M in a funding round led by Capital Grand Est, the EIC Fund, Sorbonne Venture by Audacia, Aloe Private Equit, Paris Business Angels, Capital Cell and several family offices. The company will use the proceeds to advance development of its exosome-based therapies for regenerative medicine.